Fmr LLC Purchases New Position in vTv Therapeutics Inc. (NASDAQ:VTVT)

Fmr LLC acquired a new position in vTv Therapeutics Inc. (NASDAQ:VTVT) in the 3rd quarter, HoldingsChannel reports. The firm acquired 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. Fmr LLC owned approximately 0.06% of vTv Therapeutics at the end of the most recent quarter.

Wall Street Analyst Weigh In

Separately, Alliance Global Partners began coverage on shares of vTv Therapeutics in a research note on Monday, December 9th. They set a “buy” rating and a $35.00 target price for the company.

vTv Therapeutics Stock Down 4.3 %

NASDAQ VTVT opened at $15.03 on Friday. vTv Therapeutics Inc. has a 52 week low of $7.38 and a 52 week high of $30.99. The company has a market capitalization of $47.95 million, a P/E ratio of -3.32 and a beta of 0.67. The stock’s 50-day moving average price is $14.94 and its 200-day moving average price is $16.45.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.